17-Hydroxyprogesterone Newborn Screen CAH Test
Comprehensive Newborn Screening for Congenital Adrenal Hyperplasia
The 17-Hydroxyprogesterone Newborn Screen CAH Test represents a critical advancement in pediatric healthcare, specifically designed to detect Congenital Adrenal Hyperplasia (CAH) during the earliest stages of life. This genetic screening test plays a vital role in identifying infants at risk for this serious endocrine disorder before symptoms manifest, enabling immediate medical intervention that can prevent life-threatening complications.
What Does This Test Measure?
This specialized screening test precisely measures the concentration of 17-hydroxyprogesterone (17-OHP) in newborn blood samples. 17-OHP is a steroid hormone precursor that accumulates in abnormally high levels when there’s a deficiency in the enzyme 21-hydroxylase, which is the most common cause of CAH. The test utilizes advanced fluoroimmunoassay technology to provide accurate, reliable measurements of this critical biomarker.
- Detects elevated 17-hydroxyprogesterone levels
- Identifies enzyme deficiencies in adrenal steroid synthesis
- Screens for the most common form of CAH (21-hydroxylase deficiency)
- Provides quantitative measurements for precise diagnosis
Who Should Consider This Test?
This essential screening is recommended for all newborns as part of comprehensive newborn screening programs. However, certain circumstances warrant particular attention:
- All newborns within the first few days of life
- Infants with family history of CAH or adrenal disorders
- Newborns showing ambiguous genitalia or unusual physical characteristics
- Babies experiencing feeding difficulties or poor weight gain
- Infants with electrolyte imbalances or salt-wasting symptoms
- Cases where early virilization signs are observed
Clinical Benefits of Early Detection
Early identification through the 17-Hydroxyprogesterone CAH Screen provides numerous critical benefits:
- Prevention of adrenal crises – Life-threatening salt-wasting episodes can be avoided
- Proper gender assignment – Early diagnosis helps in cases of ambiguous genitalia
- Normal growth and development – Timely treatment ensures proper physical development
- Reduced hospitalization – Early intervention decreases emergency medical needs
- Improved quality of life – Proper management leads to normal, healthy development
- Family planning guidance – Genetic counseling for future pregnancies
Understanding Your Test Results
Interpreting 17-hydroxyprogesterone levels requires careful consideration of several factors:
- Normal Range: Results within established reference ranges indicate typical adrenal function
- Borderline Results: May require repeat testing or additional evaluation
- Elevated Levels: Suggest possible CAH and warrant immediate pediatric endocrinology consultation
- Critical Values: Require urgent medical attention and treatment initiation
It’s important to note that premature infants and stressed newborns may have temporarily elevated 17-OHP levels that don’t indicate CAH. Your healthcare provider will consider gestational age, birth weight, and clinical presentation when interpreting results.
Test Details and Pricing
| Test Component | Details | Price (USD) |
|---|---|---|
| 17-Hydroxyprogesterone Newborn Screen CAH Test | Comprehensive screening for Congenital Adrenal Hyperplasia | $8 |
| Discount Price | Special promotional rate | $8 |
| Regular Price | Standard testing fee | $8 |
Sample Collection and Processing
The test requires minimal blood collection through a simple heel prick procedure. Our specialized collection method involves:
- Sample Type: 1 drop of heel prick blood each on 3 spots of filter paper
- Shipping Requirements: Samples must be shipped refrigerated or frozen
- Documentation: Complete clinical details and drug history must accompany sample
- Turnaround Time: Results typically available within 1 week
Nationwide Accessibility
We proudly serve families across the United States with convenient testing locations in all major metropolitan areas including New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, and San Jose. Our network of certified collection centers ensures that every newborn has access to this life-saving screening.
Take Action for Your Baby’s Health
Don’t leave your newborn’s health to chance. The 17-Hydroxyprogesterone CAH Screen provides peace of mind and potentially life-saving information. Our team of genetic specialists and pediatric endocrinologists are ready to assist you with this critical screening.
Call or WhatsApp us today at +1(267) 388-9828 to schedule your newborn’s screening appointment. Early detection makes all the difference in managing Congenital Adrenal Hyperplasia and ensuring your baby’s healthy development.
Trust General Genetics Corporation for comprehensive genetic testing services backed by decades of expertise in pediatric endocrinology and genetic disorder screening. Your baby’s health is our highest priority.